30 November 2018 - - US-based biopharmaceutical company Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has priced an underwritten public offering of 16,176,471 shares of its common stock, offered at a price to the public of USD 17.00 per share, the company said.

The gross proceeds from this offering to Acadia are expected to be approximately USD 275m, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Acadia.

Acadia has granted the underwriters a 30-day option to purchase up to an aggregate of 2,426,470 additional shares of common stock.

The offering is expected to close on November 30, 2018, subject to customary closing conditions.

BofA Merrill Lynch, J.P. Morgan Securities LLC and Goldman Sachs and Co. LLC are acting as the joint book-running managers for the offering. Cowen and company, LLC is acting as lead manager and Cantor Fitzgerald and Co., JMP Securities LLC and Needham and company, LLC are acting as co-managers for the offering.

Acadia is a biopharmaceutical company focused on the development and commercialisation of innovative medicines to address unmet medical needs in central nervous system disorders.

Acadia has developed and is commercialising the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

In addition, Acadia has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder, and Rett syndrome.